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BACKGROUND: Hemopressin, a nonapeptide (PVNFKFLSH: HP) derived from the  chain of
hemoglobin was shown to interact specifically with brain cannabinoid CB1 receptors. Therefore,
it seems to be the only peptide structure with cannabinoid activities. Our goal in this study was
to further characterize this peptide and to clarify the antinociceptive potency of the polyunsatu-
rated fatty acid derivates, 2-arachidonoyl-glycerol (2-AG) and anandamide, by investigating their
effects on mechanical allodynia at the spinal level.
METHODS: HP was prepared on solid phase by in situ neutralization. After chronic intrathecal
catheterization, mechanical hypersensitivity was produced in male Wistar rats by injection
of carrageenan (300 g/30 L) into the tibiotarsal joint of one of the hind legs. Three hours after
carrageenan administration, the ligands were administered intrathecally. The mechanical
threshold was assessed using a dynamic aesthesiometer.
RESULTS: 2-AG (1–200 g) and anandamide (10–200 g) decreased carrageenan-induced
mechanical allodynia in a dose-dependent manner, whereas HP had no antinociceptive effect in
a wide dose range (0.3–30 g). The effect of 2-AG was prevented by the CB1 receptor antagonist
AM 251, but not by the CB2 antagonist SSR144528-2. HP (3 and 30 g) also inhibited the effect
of 2-AG. None of the ligands influenced the degree of edema.
CONCLUSIONS: HP posttreatment had no effect on mechanical allodynia, whereas spinally
injected 2-AG and anandamide were potent drugs. (Anesth Analg 2012;114:1346–52)
Both natural and synthetic cannabinoids (CBs) actingon G protein–coupled CB1 and CB2 receptors cansuppress responses to acute and persistent noxious
stimulation.1 CB1 receptors are expressed mainly in the
central nervous system and in peripheral tissues.2,3 CB2
receptors occur predominantly peripherally in immune
cells, but recently they have also been found in the brain,
spinal cord, and in the dorsal root ganglia (DRG), mainly
on glial cells.1,4–7 A major limitation to the use of CB for
therapeutic purposes is the profile of side effects (such as
dysphoria) and potential abuse. An alternative approach,
which may prevent such side effects, is to influence the
endogenous CB system.
Hemopressin (HP), a nonapeptide (H-PVNFKFLSH-OH),
is a product of the hemoglobin  chain, discovered in rat
brain and so named because it can cause small decreases in
arterial blood pressure.8,9 A number of in vitro studies
show that HP acts as a CB1 receptor inverse agonist, and it
can act on both peripheral and central pain pathways in
vivo.10–12 These studies showed that HP pretreatment
caused antinociceptive effects at systemic, local, and spinal
levels. The authors proposed that after CB1 blockade by the
inverse agonist HP, the released endocannabinoids might
induce antinociception by interfering with other pain trans-
mission mechanisms.12 Our primary goal was to synthesize
this peptide and to determine the effects of HP posttreat-
ment on the mechanical pain threshold in a joint inflam-
mation model at the spinal level.
The family of endocannabinoids comprises sev-
eral polyunsaturated fatty acid derivates, such as
N-arachidonoylethanolamine (anandamide) and 2-
arachidonoyl-glycerol (2-AG).13,14 Anandamide was char-
acterized as an endogenous eicosanoid with moderate
affinity for the CB1 and CB2 receptors.
13 However, anand-
amide activates other receptors as well, including the
capsaicin-sensitive transient receptor potential vanilloid 1
channels (TRPV1), and some of its effects (such as antino-
ciception) may be at least partially attributed to TRPV1
activation.15–23 As for the lipid derivative 2-AG, it is a full
agonist of CB1 and CB2 receptors with no direct binding to
the TRPV1 receptor.14 Some studies have investigated its
antinociceptive potency at systemic and peripheral lev-
els.14,24–27 However, there are no data either about the
effect of 2-AG after intrathecal administration, or about the
effect of anandamide on mechanical allodynia at the spinal
level. Therefore, our secondary goal was to determine the
antinociceptive potency of 2-AG and anandamide in the
above-mentioned circumstances. Finally, we also sought to
determine the consequences of the administration of syn-




Amino acid derivatives and resins were purchased from
Bachem AG (Bubendorf, Switzerland) and Sigma (St. Louis,
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MO); coupling agents were from Calbiochem–Novabiochem
AG (La¨ufelingen, Switzerland). All other chemicals and sol-
vents were of analytical grade from commercial sources.
The following drugs were administered in the in vivo
experiments: -carrageenan (Sigma-Aldrich Ltd., Budapest,
Hungary), 2-AG (Tocris Bioscience, Bristol, UK), anand-
amide (Sigma-Aldrich Ltd.), AM 251 (CB1 receptor antag-
onist; Tocris Bioscience), and SSR144528-2 (SSR) (CB2
receptor antagonist; a generous gift from Sanofi Aventis,
Paris, France).
Carrageenan and HP were dissolved in physiological
saline. Anandamide and 2-AG were dissolved in ethanol:
Tween  2:1, respectively. Stock solutions were diluted
with saline to a final ethanol concentration of 10%. AM 251
and SSR were dissolved in dimethyl sulfoxide (Sigma-
Aldrich, Ltd.) and ethanol and it was further diluted with
distilled water. The concentration of dimethyl sulfoxide
and ethanol was 15% and 9%, respectively. Intrathecally
administered drugs were injected over 120 seconds in a
volume of 10 L, followed by a 10-L flush of physiological
saline.
In Vitro Experiments: Synthesis of HP
HP (H-Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His-OH) was pre-
pared by in situ neutralization solid-phase peptide synthesis
on Boc-His(Tos)-PAM (0.46 mmol/g loading) resin using
N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-
methylmethanaminium tetrafluoroborate N-oxide (TBTU)
as coupling agent. Completion of the couplings was tested by
the Kaiser test. Removal of the orthogonal protecting groups
and cleavage of the peptide from the resin were achieved by
anhydrous hydrogen fluoride (10 mL/g peptide-resin) in the
presence of 10% (v/v) anisole and 10% (v/v) dimethyl sulfide
at 0°C. The crude peptide was precipitated with diethyl ether
from the trifluoroacetic acid (TFA) solution and then purified
by reversed phase high-performance liquid chromatography
(RP-HPLC) on a Vydac 218TP1010 semipreparative column
(250 10 mm, 12 m; Grace, Deerfield, IL) with a gradient of
acetonitrile (0.08% TFA) in water (0.1% TFA). The purity of
the peptide was examined by analytical RP-HPLC and its




The animal surgery and testing procedures were approved
by the Institutional Animal Care Committee of the Univer-
sity of Szeged, Faculty of Medicine. Male Wistar rats
(weight, 232  2.0 g) were anesthetized with a mixture of
ketamine hydrochloride and xylazine (72 and 8 mg/kg
intraperitoneally, respectively). An intrathecal catheter (PE-10
tubing, inside diameter 0.28 mm; outside diameter 0.61
mm; Intramedic, Clay Adams, Becton Dickinson, Parsip-
pany, NJ) was inserted through the cisterna magna and
passed 8.5 cm caudally into the subarachnoid space28 to
place the catheter tip between the vertebrae T12 and L2,
corresponding to the spinal segments that innervate the
hindpaws.29 After the surgery, the rats were housed sepa-
rately, and they had free access to food and water. Rats
exhibiting postoperative neurologic deficits (approximately
10%) or those that did not show paralysis of one of the
hindpaws after 100 g lidocaine were excluded.29 The rats
were allowed to recover for at least 4 days before the testing
and they were assigned randomly to the treatment groups
(6–15 rats per group). The observer was blinded to the
treatment administered in all cases.
Carrageenan-Induced Inflammation
Inflammation was elicited by injecting carrageenan (300
g/30 L) into one of the tibiotarsal joints (on the para-
lyzed side during lidocaine administration).29,30 Carra-
geenan was given to gently restrained conscious animals,
using a 27-gauge needle, without anesthesia, so as to
exclude any drug interaction. These injections did not elicit
any sign of major distress. This way hyperalgesia was
induced, peaking at 2 to 3 hours after the injection. To
determine the changes in the size of the inflamed joint, we
measured the anteroposterior and mediolateral diameter of
the paw at the level of the ankle joint with a digital caliper.
The cross-sectional area was calculated with the formula
a b , where a and b signify the radius in the 2 aspects.
Behavioral Nociceptive Testing
The threshold of withdrawal from mechanical stimulation
to the plantar aspect of the hindpaws was assessed using
the Dynamic Aesthesiometer apparatus (mod-37450; Ugo
Basile, Comerio, Italy), which consists of an elevated wire
mesh platform to allow access to the ventral surface of the
hindpaws. Before baseline testing, each rat was habituated
to the testing box for at least 20 minutes. A steel rod
(diameter 0.5 mm) was pushed against the hindpaw with
ascending force. The force ranged from 0 to 50 g over an
8-second period. When the animal withdrew the hindpaw,
the mechanical stimulus was automatically stopped, and
the force at which the animal withdrew the paw was
recorded at 0.1-g correctness.
Experimental Protocol
After baseline determination of joint diameter and me-
chanical paw withdrawal threshold (precarrageenan base-
line value at 180 minutes), carrageenan was injected.
These measurements were performed again 3 hours after
carrageenan injection (postcarrageenan baseline values at 0
minutes). After postcarrageenan baseline determination,
HP (0.3–30 g), 2-AG (1–200 g), or anandamide (10–200
g) was given intrathecally, and mechanical sensitivity was
defined at 10, 20, 30, 45, 60, 75, 90, and 105 minutes
postadministration. The control group received physiolog-
ical saline (vehicle of HP) or vehicle of 2-AG/anandamide
(see Methods). Because vehicle-treated groups did not
differ from the saline-treated, we merged the data of these
animals.
To determine the involvement of CB1 and CB2 receptors
in the effects of 2-AG, separate groups of animals were
pretreated with AM 251 (antagonist of CB1 receptors, 10
g) or SSR (antagonist of CB2 receptors, 15 g) 20 minutes
before 200-g 2-AG injection. The control group was in-
jected with vehicles of 2-AG and CB antagonists. To inves-
tigate the potential antagonistic effects of HP on the
2-AG–induced antinociception, we coadministered 3 or 30
g HP with 200 g 2-AG.
At the end of the experiment, the joint diameters were
measured again. As for the behavioral changes, we did not
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observe any sign of altered behavior (i.e., immobility,
flaccidity, excitation, or motor weakness), except for when
100 or 200 g of anandamide was administered. Anand-
amide in these high doses caused temporary (during the
injection) vocalization and excitation, suggesting a pain-
inducing potential of anandamide.23,25 Animal suffering
and the number of animals per group were kept at a
minimum.
Statistical Analysis
Data are presented as means  SEM. Data sets were exam-
ined by repeated measures analysis of variance (ANOVA).
Post hoc comparisons were performed with the Fisher LSD
test. A P value 0.05 was considered significant. Data analy-
ses were performed with the STATISTICA for Windows
software (Statistica Inc., Tulsa, OK).
RESULTS
In Vitro Experiments: Synthesis
HP was prepared by manual solid-phase peptide synthesis
using in situ neutralization Boc chemistry. The peptide was
purified to homogeneity by semipreparative RP-HPLC and
its molecular weight was confirmed by mass spectrometry.
To investigate the hydrolytic stability of the peptide, it was
dissolved in phosphate-buffered saline and the resulting
solutions were incubated at ambient temperature for 10
hours. During the incubation period, samples were taken
and analyzed by RP-HPLC. HP was found to be stable,




Three hours after the injection of carrageenan into the
ankle, there was a significant (P  0.01) increase in joint
cross-sectional area compared with preinjection control
levels (from 36  0.1 mm2 to 73  0.5 mm2). This conspicu-
ous increase in joint size was a result of edema formation,
confirming that carrageenan treatment resulted in an in-
flammatory reaction. None of the treatments influenced the
degree of edema; the cross-section of the ankle was 72 0.5
mm2 at the end of the experiments, which did not differ
from the postcarrageenan baseline value (to 73  0.5 mm2).
Mechanosensitivity
The basal mechanical withdrawal threshold was 45 0.4 g,
and carrageenan did cause a significant decrease in paw
withdrawal threshold on the inflamed side (10 0.3 g), but
it did not have a significant influence on the noninflamed
side. None of the treatments changed the mechanosensitiv-
ity on the normal side; therefore, results were analyzed
only on the inflamed paws.
HP caused neither a significant antiallodynic effect
compared with the control group, nor were any motor
impairments observed in this wide dose range (0.3–30 g)
(Fig. 1A).
2-AG by itself produced a dose-dependent antiallodynic
effect, which developed gradually, and reached a maxi-
mum between 45 and 60 minutes (Fig. 1B). ANOVA with
repeated measures showed significant effects of treatment
(F4,48  4.7, P  0.005) and time (F9432  94.3, P  0.001).
Thus, 1 g 2-AG was ineffective, whereas 200 g caused a
prolonged antinociceptive effect.
Anandamide elicited a dose-dependent antinociceptive
effect, which reached maximum at approximately 20 min-
utes after administration (Fig. 1C). ANOVA with repeated
measures showed significant effects of treatment (F4,47 
5.2, P  0.005), time (F9423  68.5, P  0.001), and
interaction (F36,423  1.9, P  0.005). Thus, 10 g anand-
amide was ineffective, whereas 200 g caused a prolonged
effect.
Regarding the effects of antagonists AM 251 and SSR at
CB1 and CB2 receptors, respectively, none of these sub-
stances alone influenced the pain threshold (Fig. 2, A and
B). AM 251 pretreatment antagonized the antiallodynic
effect of 2-AG (200 g), whereas SSR did not influence it
(Fig. 2, A and B). Cotreatment of 3 g or 30 g HP with 200
g 2-AG significantly decreased the antinociceptive effect
of 2-AG (Fig. 2, C and D).
DISCUSSION
Our results showed that HP is a stable peptide, and its
intrathecal administration after induction of joint inflam-
mation does not influence mechanical allodynia in a wide
dose range, but it does inhibit the antinociceptive effects of
2-AG.
Only a few studies investigated the in vivo and in vitro
characteristics of HP. Conformation-state sensitive antibod-
ies were used for the investigation of binding characteris-
tics of HP to different opioid, CB, adrenergic, bradykinin,
and angiotensin receptors in cell lines and striatum.12 It has
been found that HP is an inverse agonist of CB1 receptors,
thus HP is able to block the constitutive activity of CB1 but
not CB2 receptors.
12 A recent study demonstrated that HP
can antagonize CB1 agonist-induced internalization of the
CB1 receptors in vitro.
10 As for the few earlier in vivo
results, it was observed that HP causes hypotension by
activation of nitric oxide release,8,9,31 and it induces hypo-
phagia only in mice with functional CB1 receptors.
10
Regarding the antinociceptive potency of HP, Dale et al.11
found that intraplantarly administeredHP (0.1–20 g) did not
affect the paw pressure threshold in the noninflamed paws,
but cotreatment with carrageenan or bradykinin significantly
decreased the development of mechanical allodynia, as mea-
sured with the paw pressure test, and the effect was not
inhibited by an opioid antagonist. Because the contralaterally
administered HP was also effective in this respect, the data
suggest systemic effects of the ligand. Orally (50 or 100
g/kg) or intrathecally (0.5 or 5 g) administered HP pre-
treatments were also effective in the same test.12 Intraperi-
toneally administered HP (50 or 500 g/kg) exhibited
marked antinociceptive potency in the acetic acid–induced
visceral nociception model. This high dose of HP did not
impair motor activity or alter pentobarbital-induced sleep-
ing time, indicating the absence of unwanted sedative or
motor side effects. Unfortunately, we did not observe
similar antinociceptive effects in our model. It is possible
that the controversial results might be attributable to dif-
ferences in the timing of administration. That is, we applied
HP after the mechanical allodynia had been established
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(posttreatment), whereas earlier studies prevented the de-
velopment of the hyperalgesia (pretreatment). Further-
more, there were differences regarding either the applied
pain test (paw pressure versus von Frey) or the site of
administration of carrageenan (intraplantar versus intra-
joint administration). In agreement with our results, the
latest evidence suggests inefficacy of HP at the spinal level
in an acute heat pain test and in a neuropathic pain
model.32,33 As for the HP pretreatment before formalin
administration, a low dose of HP (3 g) decreased, but a
higher dose (10 g) enhanced the formalin-induced nocif-
ensive behavior. The authors observed the inefficacy of HP
as an antagonist after CB1 receptor activation. This is in
contrast with our results, because HP, similarly to the
synthetic CB1 antagonist, antagonized the antinociceptive
effect of 2-AG in our study. We suppose that the differences
in the pain models and the applied CB ligand (WIN
55,212-2 versus 2-AG) might be the explanation for the
different results.
Spinally administered anandamide and 2-AG signifi-
cantly decreased mechanical inflammatory pain sensitivity.
The use of CB for the management of a wide range of painful
disorders has been well documented at spinal, supraspinal,
and peripheral levels,1,4,34 whereas endogenous ligand data
are scarce, especially at the spinal level. Earlier studies
showed that intrathecal anandamide decreased acute heat
pain sensitivity (in hotplate and tail-flick tests) and
carrageenan-induced thermal hyperalgesia in rodents, and
that both the CB1 and TRPV1 receptors have a role in these
effects.23,35,36 To our knowledge, we are the first to offer
evidence to suggest that anandamide inhibits mechanical
allodynia at the spinal level as well. Because several systems
may be influenced by anandamide (e.g., CB, TRPV1, glycine,
and serotonin-3 receptors), their net effect may be observed
under these circumstances.15,16,37–40 Because the high dose of
anandamide caused temporary pain, the desensitization of
TRPV1 receptors can also be involved in its antinociceptive
effect, as suggested earlier.18,23 Therefore, it is possible that
alterations in the release of excitatory and inhibitory transmit-
ters can modify the activation of projection neurons, either
presynaptically from primary sensory neurons or postsynap-
tically from interneurons, or both.
Figure 1. Time course and dose-dependent effects of hemopressin (HP) (A), 2-arachidonoyl-glycerol (2-AG) (B), and anandamide (ANA) (C) on
the inflamed side. The arrows show the injections. Each point signifies the mean  SEM of the results. *Significant (P  0.05) difference
compared with the vehicle-treated group.
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2-AG, similarly to anandamide, reduced allodynia in the
carrageenan-induced arthritis model, and its antinociceptive
effect was inhibited by a CB1 antagonist, whereas it was not
influenced by a CB2 antagonist. This is the most abundant
endogenous CB, and its concentration in the brain is 50 to 500
times higher than that of anandamide. It has also been
identified peripherally.2,41 2-AG is a full agonist for CB1 and
CB2 receptors with no direct binding to the TRPV1 receptor.
14
It is also a substrate for cyclooxygenase-2, and 2-AG is capable
of suppressing an increase of cyclooxygenase-2 expression by
activating the CB1 receptors.
42,43 There is only little evidence
to support the antinociceptive potency of 2-AG. Endogenous
2-AG has been implicated as a major transmitter involved
in endocannabinoid-mediated stress-induced analgesia.44,45
Thus 2-AG, but not anandamide, is mobilized in the
lumbar spinal cord after exposure to footshock stress, and
spinal 2-AG levels show marked correlation with stress-
induced antinociception.45,46 Additionally, intrathecal ad-
ministration of an inhibitor of the 2-AG hydrolyzing
enzyme, monoacylglycerol lipase, enhances stress-induced
antinociception in a CB1-dependent manner.
45 In systemic
administration to mice, 2-AG (50% effective dose  12.5
mg/kg) caused antinociception in acute pain tests, immo-
bility, reduction of spontaneous activity, and decrease of
rectal temperature.14,24 Topical administration of 2-AG also
decreased the nocifensive behavior in a formalin test,
decreased mechanical allodynia and thermal hyperalgesia
in a neuropathic pain model, and it was also effective in the
alleviation of inflammatory joint pain.25–27 The local anti-
nociceptive effects of 2-AG were prevented by CB1 and/or
CB2 antagonists.
25–27 As far as the spinal level is concerned,
we are the first to show its antinociceptive potency, and
that the effect is reversed by a CB1 antagonist drug (but not
by a CB2 antagonist), suggesting that the antiallodynic
effect of 2-AG is mainly attributable to the activation of CB1
receptors at the spinal level. CB1 receptors, the molecular
targets of 2-AG, are located on primary afferent fiber
endings and/or on intrinsic interneurons in the dorsal horn
of the spinal cord47,48; therefore, their activation could have
led to the observed antinociception.
Figure 2. The effects of AM 251 (A), SSR (B), and hemopressin (HP) (C and D) on the antinociceptive effects of 200 g 2-arachidonoy-glycerol
(2-AG). The arrows show the injections. Each point signifies the mean  SEM. *Significant (P  0.05) difference compared with the
vehicle-treated group. #Significant differences between the 2-AG and 2-AG  antagonist/HP-treated groups.
Antinociceptive Potency of Endocannabinoids at Spinal Level
1350 www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA
It is important to consider that these ligands can influ-
ence the activity of neurons in DRG too, because the CB
receptors can be found on DRG neurons,49,50 and it has
been shown that intrathecal injection of sodium fluorescein
results in massive staining in the DRG both in the cellular
and fiber portions.51 As for the ineffectivity of CB1 and CB2
antagonists alone on inflamed and noninflamed sides, a
number of scenarios may be suggested. First, it might be
supposed that the mechanical pain threshold after carra-
geenan administration (approximately 10–15 g) is a very
low value, which could not be further decreased by an
antagonist. However, the threshold on the normal side did
not change either; therefore, this is not likely. Another
possibility is that the endogenously released CBs have no
significant inhibitory effect on the mechanical threshold in
inflammatory circumstances, either on the normal or on
the inflamed side. Similar results were found in a bone cancer–
induced pain model52; however, other studies have shown
that intrathecal injection of CB1 receptor antagonists can
evoke nociceptive responses.53,54 It is assumed that the differ-
ences in the pain models can lead to these controversial
findings. However, the level of the released endogenous CBs
was not determined in our study; therefore, it cannot be
decided whether this is attributable to lack of production or
lack of effect of endogenous CB agonists.
In conclusion, we found that HP was not capable of
influencing the established mechanical allodynia in a
model of arthritic pain, but inhibited the antinociceptive
effects of 2-AG at the spinal level. Furthermore, these
findings are the first to demonstrate the antinociceptive
potency of 2-AG at the spinal level, and the effect of
anandamide on mechanical allodynia in an arthritic pain
model.
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